<clinical_study>
<study_id>
<org_name>
  Boehringer
</org_name>
<org_full_name>
  Boehringer Ingelheim Pharmaceuticals
</org_full_name>
<org_study_id>
  248.538
</org_study_id>
<nct_id>
  NCT00144300
</nct_id>
</study_id>
<brief_title>
<textblock>
  A Two-Year Open-Label, Randomized, Parallel Group Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson&apos;s Disease Patients
</textblock>
</brief_title>
<official_title>
<textblock>
  A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson&apos;s Disease Patients
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Boehringer Ingelheim Pharmaceuticals
</agency>
</lead_sponsor>
</study_sponsor>
<oversight_info>
</oversight_info>
<brief_summary>
<textblock>
  To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Recruiting
</status>
<date>
2007-01 
</date>
</status_block>
<start_date>
<date>
  2005-01
</date>
</start_date>
<end_date>
<date>
  2011-03
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<last_data_entry_date>
<date>
</date>
</last_data_entry_date>
<phase_block>
<phase>
  Phase 4
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<primary_outcome>
  To determine if there is any difference in the presence of retinal deterioration in Parkinson&apos;s disease patients treated with pramipexole versus ropinirole.
</primary_outcome>
<secondary_outcome>
  To assess and monitor safety and tolerability of pramipexole versus ropinirole in Parkinson&apos;s disease patients; to assess progression of Parkinson&apos;s disease over the study period.
</secondary_outcome>
<condition>
  Parkinson Disease
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  pramipexole
</primary_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Diagnosis and main criteria for inclusion:   Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study (all time periods are calculated from randomization.):
  1. Patients with idiopathic Parkinson&apos;s disease for at least 2 years confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity; and characterized as Stage I-III by the Modified Hoehn and Yahr Scale.
  2. On stable dosage of levodopa for at least 4 weeks. 
  3. Age between 30 and 80 years old 
  4. Women of childbearing potential must have a negative serum beta-HCG pregnancy test at the Screen (Baseline) visit and the patient must use adequate contraceptive methods.
  5. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  6. Patients who are willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  7. HAMD total score of greater than 15.
  8. Mini-Mental  State Examination (MMSE) score greater than 23.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<patients>
</patients>
<expected_enrollment>
  300
</expected_enrollment>
<gender>
  Both
</gender>
<minimum_age>
  30 Years
</minimum_age>
<maximum_age>
  80 Years
</maximum_age>
</eligibility>
<investigator>
<role>
</role>
<name>
  Boehringer Ingelheim Study Coordinator
</name>
<affiliation>
<agency>
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Boehringer Ingelheim Study Coordinator
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
  clintriage@rdg.boehringer-ingelheim.com
</email>
</contact>
<location>
<facility>
<name>
  University of Alabama at Birmingham
</name>
<address>
<city>
  Birmingham
</city>
<state>
  Alabama
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Little Rock
</city>
<state>
  Arkansas
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Fountain Valley
</city>
<state>
  California
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  USC / Keck school of Medicine
</name>
<address>
<city>
  Los Angeles
</city>
<state>
  California
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Attn: Jack Mariotti, CFO
</name>
<address>
<city>
  New Haven
</city>
<state>
  Connecticut
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  1501 N.W. 9th Ave
</name>
<address>
<city>
  Miami
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Attn:  Corinne Walters
</name>
<address>
<city>
  Tampa
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Tampa
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Medical College of Georgia, Department of Neurology
</name>
<address>
<city>
  Augusta
</city>
<state>
  Georgia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  1841 Clifton Rd.
</name>
<address>
<city>
  Atlanta
</city>
<state>
  Georgia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Attn: Fund Accounting, 273 TOB
</name>
<address>
<city>
  Chicago
</city>
<state>
  Illinois
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  University of Maryland Medical System
</name>
<address>
<city>
  Baltimore
</city>
<state>
  Maryland
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  26400 W. 12 Mile Road
</name>
<address>
<city>
  Southfield
</city>
<state>
  Michigan
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  10 Union Square
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  710 W. 168th Street
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Mount Sinai Medical Center
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Charlotte
</city>
<state>
  North Carolina
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Duke Health Center at Morreene Road
</name>
<address>
<city>
  Durham
</city>
<state>
  North Carolina
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  330 S. 9th Street
</name>
<address>
<city>
  Philadelphia
</city>
<state>
  Pennsylvania
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  University of Tennessee, Memphis
</name>
<address>
<city>
  Memphis
</city>
<state>
  Tennessee
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  Eddy Scurlock Stroke Center
</name>
<address>
<city>
  Houston
</city>
<state>
  Texas
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
  West Virginia University Dept. of Neurology
</name>
<address>
<city>
  Morgantown
</city>
<state>
  West Virginia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<initial_release_date>
  2005-09-02
</initial_release_date>
<last_release_date>
2007-01-12 
</last_release_date>
</clinical_study>
